Aomo Pharma Inc., the U.S. subsidiary of Adamerck, is a biotechnology company founded in 2000 with the mission of developing and commercializing high-quality, innovative therapeutics that mostly address unmet clinical needs.
The company’s development pipeline comprises more than ten first-in-class drug candidates targeting a broad range of therapeutic areas, including anesthesia, cardiovascular diseases, ophthalmology, neurodegenerative disorders and oncology.
Among its proprietary drug candidates, adamgammadex (AOM0498) is a patented selective neuromuscular blockade reversal agent. Two pivotal Phase III clinical trials in China have been successfully completed, and the New Drug Application (NDA) was accepted by the National Medical Products Administration (NMPA) on September 18, 2024. On June 30, 2026, AOM0498 received NMPA approval for the reversal of neuromuscular blockade induced by rocuronium bromide in adult patients.
Development of adamgammadex is also progressing internationally. The End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) was successfully completed on September 28, 2022, and multi-regional clinical trials (MRCTs) across the United States, Europe, and Japan are scheduled to commence in 2026.